Trifluridine
Code | Size | Price |
---|
TAR-T1428-25mg | 25mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1428-1mL | 1 mL * 10 mM (in DMSO) | £121.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1428-50mg | 50mg | £123.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1428-100mg | 100mg | £140.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1428-200mg | 200mg | £179.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Trifluridine is a fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity.
CAS:
70-00-8
Formula:
C10H11F3N2O5
Molecular Weight:
296.202
Pathway:
Cell Cycle/Checkpoint; Microbiology/Virology; DNA Damage/DNA Repair
Purity:
0.9982
SMILES:
OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F
Target:
Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; HSV
References
1. Yamashita F, et al. Cancer Chemother Pharmacol,2015 Jun 18.
2. Sakamoto K, et al. Int J Oncol,2015, 46(6), 2327-2334.
3. Germano A, et al. Mol Cell Endocrinol. 2014 Jan 25;382(1):1-7.
4. Rootman DS, et al. Invest Ophthalmol Vis Sci,1989, 30(4), 678-683.
5. Tanaka N, et al. Oncol Rep,2014, 32(6), 2319-2326.